Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do patients with low-risk and intermediate-risk prostate cancer benefit from androgen deprivation?

Nature Clinical Practice Urology volume 2, pages 160–161 (2005)Cite this article

boxed-textCiezki JP et al. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys 60: 1347–1350

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pilepich MV et al. (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized trial of the Radiation Therapy Oncology Group. Urology 45: 616–623

    Article  CAS  Google Scholar 

  2. Bolla M et al. (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295–300

    Article  CAS  Google Scholar 

  3. Zelefsky MJ et al. (2004) Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 59: 1053–1061

    Article  Google Scholar 

  4. D'Amico AV et al. (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827

    Article  CAS  Google Scholar 

  5. Pollack A et al. (2002) Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53: 1097–1105

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Michelmore, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Radiation Oncology at Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Anthony L Zietman

Authors
  1. Anthony L Zietman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony L Zietman.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Glossary

GLEASON SCORE

Sum of grades assigned to the two largest cancerous areas of tissue samples; grades range from 1 (least aggressive) to 5 (most aggressive)

BRACHYTHERAPY

Radiotherapy in which closed sources of radiation (e.g. seeds) are placed (e.g. by implantation) in or close to the area being treated

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zietman, A. Do patients with low-risk and intermediate-risk prostate cancer benefit from androgen deprivation?. Nat Rev Urol 2, 160–161 (2005). https://doi.org/10.1038/ncpuro0148

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0148

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing